BeOne Medicines (ONC) Discontinues Five Oncology Pipeline Programs and Phase 2 Clinical Trial for Rheumatoid Arthritis
Aggressive R&D Portfolio Restructuring and Focus on Core Assets
BeOne Medicines (ONC) announced in its Q1 2026 earnings report that it will significantly streamline its early-stage pipeline. Four Phase 1 oncology pipeline programs, including BG-60366, an EGFR CDAC targeting agent for non-small cell lung cancer (NSCLC); BGB-53038, a pan-KRAS inhibitor; BG-89894, a MAT2A inhibitor; and BG-68501, a CDK2 inhibitor, have been completely discontinued. Additionally, the Phase 1 trial for BGB-A3055, a CCR8-targeting antibody, has been terminated early, although the company stated that a decision on whether to dispose of the asset will be made after data analysis. This decision is based on a data-driven resource allocation strategy, reflecting an intention to reallocate funds from early-stage R&D to focus on core pipeline programs with a higher probability of success.
Significant Loss of Licensed Asset Value and Damage to Reputation
Some of the programs being discontinued were high-value assets that BeOne Medicines (ONC) had in-licensed, which has caused considerable concern in the market. For example, BG-68501, a CDK2 inhibitor, was acquired from Ensem Therapeutics in 2023 for a total of USD 1.33 billion, and BG-89894, a MAT2A inhibitor, was licensed from CSPC Zhongqi in late 2024 for a total of USD 1.835 billion, including an upfront payment and near-term payments. The trial was halted just over a year after the deal. While this is a necessary measure to improve the efficiency of R&D funding, the early failure of these large milestone agreements could erode investor confidence in technology in-licensing partnerships. While aggressive early-stage termination of new drug development may have a positive impact on long-term cash flow, it is difficult to avoid short-term impairment of corporate value.
Setback in Entering the Autoimmune Disease Market
In addition to the oncology pipeline, a difficult decision has also been made in the area of autoimmune diseases. BeOne Medicines (ONC) has decided to discontinue the Phase 2 clinical trial of BGB-45035, an IRAK4 protein degrader for the treatment of rheumatoid arthritis. While the global rheumatoid arthritis market is estimated at USD 27 billion to USD 36 billion in 2026, the recent efficacy data did not meet expectations, leading to the termination of the trial. However, the company plans to continue the Phase 1 trial for skin diseases, leaving room for the survival of the autoimmune platform technology.
Intense Competitive Environment and Pursuit of Strategic Alternatives
BeOne Medicines (ONC)'s decision is also related to the highly competitive global oncology and autoimmune markets. For example, in the pan-KRAS field, Revolution Medicines is leading the way with Phase 3 trials showing significant improvement in survival rates in pancreatic cancer patients. In the IRAK4 degrader field, Kymera Therapeutics is also accelerating the clinical development of its next-generation compound, KT-485, through a USD 975 million partnership with Sanofi, increasing competitive pressure. As a result, BeOne Medicines (ONC) is reducing its early pipeline and focusing on a more validated approach, such as entering into an option agreement with Huahui Health in China for a PD-1, CTLA-4, and VEGF-A trispecific antibody with an upfront payment of USD 20 million and a total potential value of USD 2 billion.
BeOne Medicines (ONC)'s discontinuation of five Phase 1 oncology pipeline programs and the Phase 2 clinical trial of BGB-45035 for rheumatoid arthritis will result in impairment losses of large in-licensed assets, negatively impacting short-term corporate value. In particular, the USD 1.33 billion and USD 1.835 billion deals with Ensem and CSPC Zhongqi, respectively, have been rendered ineffective, raising concerns about the company's new drug in-licensing strategy. In the medium to long term, with Kymera's KT-485 entering clinical trials and leading the way in the USD 27 billion rheumatoid arthritis market in 2026, it is inevitable that resources will be concentrated on the company's core focus area: the trispecific antibody (option agreement value of USD 2 billion) for immuno-oncology. From a researcher's perspective, the reduction of the IRAK4 degrader's indication to a Phase 1 trial for skin diseases will provide an opportunity to analyze the limitations of target protein degradation technology in validating efficacy in autoimmune diseases. Overall, this R&D portfolio restructuring is part of a survival strategy that seeks to improve R&D pipeline efficiency while concentrating resources on core assets.